罗沙司他治疗非髓系恶性肿瘤化疗患者贫血的开放标签2期研究
这项开放标签2期研究纳入非髓系恶性肿瘤合并化疗诱导贫血(血红蛋白≤10 g/dL)且计划继续接受≥8周骨髓抑制性化疗的患者,口服罗沙司他≤16周(起始剂量2.0或2.5 mg/kg,每4周滴定)。89例可评估患者中,两剂量组在不输血情况下血红蛋白最大平均变化分别为2.4和2.5 g/dL;深静脉血栓和肺栓塞分别发生于14例(15.2%)和9例(9.8%)。
要点
- 罗沙司他2.0和2.5 mg/kg组不输血时血红蛋白最大平均变化分别为2.4和2.5 g/dL。
- 血红蛋白升高≥2 g/dL的中位时间为71天(范围57-92天)。
- 深静脉血栓发生14例(15.2%),肺栓塞9例(9.8%)。
核心结论
- 罗沙司他可提高化疗诱导贫血患者的血红蛋白, regardless of tumor type and chemotherapy regimen。
- 不良事件与晚期恶性肿瘤患者的观察结果一致。
研究设计与样本
- 开放标签2期研究,纳入非髓系恶性肿瘤合并化疗诱导贫血(血红蛋白≤10 g/dL)且计划继续接受≥8周骨髓抑制性化疗的患者。
- 口服罗沙司他≤16周,起始剂量2.0或2.5 mg/kg,每4周滴定。
- 患者分配至罗沙司他2.0 mg/kg组(n=31)或2.5 mg/kg组(n=61),其中89例可评估疗效。
主要发现
- 不输血时血红蛋白最大平均(标准差)变化:罗沙司他2.0 mg/kg组为2.4(1.5)g/dL,2.5 mg/kg组为2.5(1.5)g/dL。
- 血红蛋白升高≥2 g/dL的中位(范围)时间为71(57-92)天。
- 12例(14.5%)患者接受红细胞输注(第5周至治疗结束)。
- 深静脉血栓发生14例(15.2%),肺栓塞9例(9.8%)。
- 研究者认为与罗沙司他相关的严重不良事件3例:肺栓塞2例(2.2%),深静脉血栓1例(1.1%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anemia is a common side effect of myelosuppressive chemotherapy; however, chemotherapy-induced anemia (CIA) management options are suboptimal. We evaluated the efficacy and safety of roxadustat in this setting. This open-label Phase 2 study included patients with non-myeloid malignancies and CIA (hemoglobin [Hb] ≤10 g/dL) who had planned concurrent myelosuppressive chemotherapy for ≥8 additional weeks. Oral roxadustat was administered for ≤16 weeks (starting dose 2.0 or 2.5 mg/kg, then titrated every 4 weeks). The primary efficacy endpoint was mean maximum change in Hb within 16 weeks of baseline without red blood cell (RBC) transfusion. Patients were assigned to roxadustat 2.0 (n = 31) or 2.5 mg/kg (n = 61) starting doses, and 89 were assessed for efficacy. The mean (standard deviation) maximum Hb change from baseline without RBC transfusion was 2.4 (1.5) and 2.5 (1.5) g/dL in the roxadustat 2.0 and 2.5 mg/kg groups, respectively. Median (range) time to Hb increase of ≥2 g/dL was 71 (57-92) days. Twelve patients (14.5%) had RBC transfusions (Week 5 to the end of treatment). Roxadustat was efficacious regardless of tumor type and chemotherapy regimen. Deep vein thrombosis (DVT) and pulmonary embolism (PE) occurred in 14 (15.2%) and nine (9.8%) patients, respectively, and three had serious adverse events attributed to roxadustat in the opinion of the investigators (PE: n = 2 [2.2%]; DVT: n = 1 [1.1%]). Roxadustat increased Hb in patients with CIA regardless of tumor type and chemotherapy regimen. Adverse events were consistent with observations in patients with advanced-stage malignancies.
引用
- Glaspy J, Gabrail NY, Locantore-Ford P, et al. Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies. Am J Hematol. 2023. PMID: 36710399. doi:10.1002/ajh.26865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。